Stock·NYSE·Healthcare
Johnson & Johnson (JNJ)
- Market cap
- $615.87B
- P/E
- 28.81
- Dividend yield
- 2.07%
- Street target
- $283.50median of 23 analysts
- 52-week range
- $184.66 $281.07
The short version
Where JNJ stands today, in four lines, and what CleaRank Financial AI makes of it.
JNJ at a glance
Johnson & Johnson (JNJ): Buy, 61/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($244.12 and $265.23).
- Earnings JNJ beat estimates in 7 of its last 8 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $193.5M and bought $258K over the last 18 months.
- Valuation P/E of 28.8 against 31.9 for the Healthcare sector: broadly in line with peers (-10%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Johnson & Johnson (JNJ) Buy with a model score of 61/100.
Trend is the strongest factor in that score. The price is 4.69% above its 200-day average, and the 50-day average sits 8.65% above the 200-day. Momentum pulls the score down the most, because the MACD line is negative. The 50-day average is $265.23 and the 200-day is $244.12, and the stock gained 33.02% over the past year.
Only on CleaRank
Figures we compute ourselves from JNJ's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $255.56 is 3.6% below the 50-day simple moving average of $265.23.Price above its 200-day average ›
The price is 4.7% above the 200-day simple moving average of $244.12.50-day average above the 200-day ›
The 50-day average ($265.23) is 8.6% above the 200-day average ($244.12), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 74% of its 52-week range, between $184.66 and $281.07.
JNJ share price
Pick a period: each tab shows how far JNJ has moved over it, to the last close.
Today's trading
Where JNJ sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 28.81 is 9.7% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 6.14 is 80.7% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $16.1B on revenue of $99.3B, a net margin of 16.2%.Beat estimates in most recent reports ›
JNJ beat the EPS estimate in 7 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.07%, or $5.28 a share a year.
Key statistics
The headline figures for JNJ.
As of October 17, 2026, JNJ trades at $255.56, with a market value of $615.87B, a P/E ratio of 28.81 and a dividend yield of 2.07%.
What the numbers say
CleaRank Financial AI's reading of JNJ's valuation, growth and risks.
JNJ's trailing P/E of 28.81 is 9.7% below the Healthcare sector median P/E of 31.9, and the P/E is broadly in line with peers. Its price-to-sales ratio of 6.14 is 80.6% above the sector median P/S of 3.4.
JNJ's revenue growth lags the sector: sales rose 5.90% in the latest year, while the sector median is 8.1%. Profitability is strong, with a net margin of 16.20% and an operating margin of 25.06%. Return on equity of 32.87% sits above the sector median of 7.3%. On the balance sheet, debt-to-equity is 0.58, and the trailing dividend yield is 2.07%, or $5.28 a share per year.
Johnson & Johnson (JNJ) reported earnings on October 13, 2026 and beat the estimate by 2.78%, posting $2.59 per share against the $2.52 analysts had expected. In the following session the shares moved up 2.13%.
Over its last 8 reports, JNJ has beaten the EPS estimate in 7 of them. Even so, the stock fell in the first session after 2 of those 7 beats. For this fiscal year, analysts average an EPS estimate of $11.07, a rise of 2.6%. For next year they expect $12.17, which would be growth of 9.9%.
Normal swings for JNJ run at about 1.48% a day. Insiders sold $193.5M over the last 18 months and bought $258K, though sales of this kind are often planned in advance and say less than purchases would.
JNJ against the Healthcare sector
How JNJ compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-10% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 6, 2025, JNJ has gained 65.4% against a gain of 31.4% for XLV.
Performance against XLV
JNJ and the Healthcare sector fund over the same days.
Revenue and earnings
How much JNJ sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.0% in FY2025 to $94.2B, from $88.8B a year earlier.
Profit margin: The net margin was 28.5% in FY2025, up from 15.8% the year before.
Profitable: JNJ earned $26.8B in FY2025.
Earnings reality check
Did JNJ beat what analysts expected, and how did the stock react?
Earnings record: JNJ beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 2 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 13, 2026after close | $2.52 | $2.59 | +2.78% | +2.13% | - |
| Jul 15, 2026after close | $2.85 | $2.90 | +1.75% | +1.19% | +3.49% |
| Apr 14, 2026after close | $2.68 | $2.70 | +0.75% | -0.60% | -5.81% |
| Jan 21, 2026after close | $2.46 | $2.46 | +0.00% | +0.22% | +4.45% |
| Oct 14, 2025after close | $2.76 | $2.80 | +1.45% | +0.17% | +0.54% |
| Jul 16, 2025after close | $2.68 | $2.77 | +3.36% | -1.09% | +2.62% |
| Apr 15, 2025after close | $2.58 | $2.77 | +7.36% | +0.19% | +1.15% |
| Jan 22, 2025after close | $2.01 | $2.04 | +1.49% | +0.94% | +4.05% |
As of October 17, 2026, JNJ has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on October 13, 2026, came in 2.78% above the estimate and the stock moved +2.13% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 43.7, in neutral territory.RSI above 50 ›
An RSI of 43.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of JNJ
The score, the reasoning behind it, and what could move the price next.
Johnson & Johnson (JNJ) sends a mixed trend signal: at $255.56, it trades 3.65% below its 50-day average of $265.23 but 4.69% above its 200-day average of $244.12. The price sits near the top of its 52-week range, 9.08% below the high of $281.07 and 38.39% above the low of $184.66. With the 50-day average 8.65% above the 200-day, the averages have not yet caught up with the weaker price.
A recent pullback sits inside a stronger longer record: the price fell 4.38% over the past month, rose 1.00% over the past three months and rose 33.02% over the past year. The 14-day RSI of 43.7 is in the neutral zone, and the MACD line is negative.
Earnings beat ›
The October 13, 2026 report beat the EPS estimate by 2.78%, and the share price rose 2.13% in the first session after it.
Source: Earnings report, October 13, 2026
Rating reaffirmed ›
Guggenheim kept its Buy rating on October 7, 2026.
Source: Analyst action, Guggenheim, October 7, 2026
- Keep an eye on the two closest levels: the 20-day EMA at $259.71 overhead and the 200-day SMA at $244.12 underneath.
- The 14-day RSI reads 43.7, in the neutral zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- The share price rose 2.13% in the first session after the October 13, 2026 report. JNJ has beaten estimates in 7 of its last 8 reports.
The trend is mixed: JNJ is above its 200-day average at $244.12 but below its 50-day average at $265.23. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The nearest levels are the 200-day SMA at $244.12 below and the 20-day EMA at $259.71 above.
Johnson & Johnson's 14-day RSI of 43.7 places the stock in neutral territory, between 40 and 60.
Technical indicators
Momentum and trend for JNJ, from its daily closes.
As of October 17, 2026, with JNJ at $255.56, its 14-day RSI is 43.7 (neutral territory), its 50-day simple moving average is $265.23 and its 200-day is $244.12.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What JNJ moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, JNJ's 1-year correlation of daily returns is -0.02 with S&P 500 (SPY), -0.17 with Nasdaq 100 (QQQ), -0.15 with Bitcoin (BTC) and +0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
16 of 23 analysts rate it a buy or strong buy, 6 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $283.50 is 10.9% above the price.More buy ratings than three months ago ›
16 of 23 rate it a buy now, against 16 of 23 three months ago.
JNJ Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Guggenheim | Reiterates | Buy |
| Oct 6, 2026 | RBC Capital | Maintains | Outperform |
| Oct 5, 2026 | Citigroup | Maintains | Buy |
| Sep 29, 2026 | JP Morgan | Maintains | Neutral |
| Sep 10, 2026 | HSBC | Maintains | Buy |
| Sep 2, 2026 | UBS | Maintains | Buy |
As of October 17, 2026, 23 Wall Street analysts cover JNJ: 16 rate it a buy or strong buy, 6 a hold and 1 a sell or strong sell. Their 12-month price targets range from $190.00 to $320.00, with a median of $283.50, 10.9% above the price of $255.56.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
JNJ trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from JNJ's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much JNJ tends to move, against the market and on its own.
The long record
JNJ's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.48% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 18.0%, from February 2020 to March 2020, regained by April 2020.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $28,255, against $42,055 in the S&P 500 (SPY).
JNJ Drawdowns & Recovery
As of October 17, 2026, JNJ's worst peak-to-trough fall over the last 10 years with dividends reinvested was -18.0% (February 2020 to March 2020); it regained that peak by April 2020, 1 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into JNJ in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: JNJ trailed the S&P 500 over this period: $28,255 against $42,055.
A $10,000 investment in JNJ in October 2016 would be worth about $28,255 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to JNJ, and which have not.
Strongest month, January: an average of +3.37%, up in 7 of 10 years.
Weakest month, May: an average of -0.90%, up in 4 of 10 years.
This month, October: has averaged +0.41%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, JNJ's strongest calendar month has been January (average +3.37%, up in 7 of 10 years) and its weakest May (average -0.90%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in JNJ, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in JNJ today could grow to about $19,666 by 2036 in the base case, with a 90th-percentile outcome near $42,536 and a 10th-percentile outcome around $9,092. The simulation models price only; at today's 2.07% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
JNJ Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $335 for JNJ by 2030 in the base case, from $256 today (1.3x over 4 years). The 10th-percentile path ends near $206. These are outcomes of a Monte Carlo simulation run on JNJ's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $214 | $273 | $349 | |
| 2028 | $207 | $293 | $413 | |
| 2029 | $205 | $313 | $478 | |
| 2030 | $206 | $335 | $546 | |
| 2031 | $208 | $358 | $618 |
Method: a lognormal simulation of JNJ's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
JNJ insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $258K on the open market and sold $193.5M.
As of October 17, 2026, JNJ insiders reported 20 open-market sales worth $193.5M and 1 open-market purchase worth $258K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Timothy Schmid
Officer
|
Sell | 33.6K | $9.2M |
| Sep 2, 2026 | Timothy Schmid
Officer
|
Option | 33.6K | $4.9M |
| Aug 17, 2026 | Jennifer L Taubert
Officer
|
Sell | 15.0K | $4.0M |
| Aug 17, 2026 | Jennifer L Taubert
Officer
|
Option | 15.0K | $1.7M |
| Aug 13, 2026 | Joaquin Boix Duato
Chief Executive Officer
|
Sell | 123.3K | $32.2M |
| Aug 13, 2026 | Joaquin Boix Duato
Chief Executive Officer
|
Option | 123.3K | $14.3M |
| Aug 6, 2026 | Elizabeth Forminard
Officer
|
Sell | 15.9K | $4.1M |
| Aug 6, 2026 | Elizabeth Forminard
Officer
|
Option | 9.3K | $1.2M |
| Aug 5, 2026 | Joaquin Boix Duato
Chief Executive Officer
|
Sell | 48.5K | $12.5M |
| Jul 20, 2026 | Vanessa Broadhurst
Officer
|
Sell | 23.1K | $5.8M |
| Jul 20, 2026 | Vanessa Broadhurst
Officer
|
Option | 23.1K | $3.0M |
| Jun 11, 2026 | Kathryn E Wengel
Chief Technology Officer
|
Sell | 10.0K | $2.4M |
| Jun 11, 2026 | Kathryn E Wengel
Chief Technology Officer
|
Option | 10.0K | $1.2M |
| May 1, 2026 | John C Reed
Officer
|
Grant | 25.3K | - |
| Feb 27, 2026 | Robert J Decker
Officer
|
Sell | 4.1K | $1.0M |
| Feb 27, 2026 | Robert J Decker
Officer
|
Option | 4.1K | $471.4K |
| Feb 20, 2026 | Timothy Schmid
Officer
|
Sell | 1.3K | $324.8K |
| Feb 18, 2026 | Timothy Schmid
Officer
|
Sell | 22.6K | $5.5M |
| Feb 18, 2026 | Timothy Schmid
Officer
|
Option | 29.6K | $2.7M |
| Feb 17, 2026 | Joseph J Wolk
Chief Financial Officer
|
Sell | 89.7K | $21.8M |
| Feb 17, 2026 | James D Swanson
Chief Technology Officer
|
Sell | 62.1K | $15.1M |
| Feb 17, 2026 | John C Reed
Officer
|
Sell | 53.9K | $13.1M |
| Feb 17, 2026 | Vanessa Broadhurst
Officer
|
Sell | 6.2K | $1.5M |
| Feb 17, 2026 | John C Reed
Officer
|
Option | 54.8K | $8.1M |
| Feb 17, 2026 | James D Swanson
Chief Technology Officer
|
Option | 73.1K | $10.2M |
| Feb 17, 2026 | Joseph J Wolk
Chief Financial Officer
|
Option | 107.8K | $8.2M |
| Feb 13, 2026 | Vanessa Broadhurst
Officer
|
Grant | 10.0K | - |
| Feb 13, 2026 | Robert J Decker
Officer
|
Grant | 3.7K | - |
| Feb 13, 2026 | Joaquin Boix Duato
Chief Executive Officer
|
Grant | 84.7K | - |
| Feb 13, 2026 | Elizabeth Forminard
Officer
|
Grant | 16.4K | - |
| Feb 13, 2026 | Kristen Mulholland
Officer
|
Grant | 5.0K | - |
| Feb 13, 2026 | Jennifer L Taubert
Officer
|
Grant | 32.2K | - |
| Feb 13, 2026 | Kathryn E Wengel
Officer
|
Grant | 15.6K | - |
| Feb 6, 2026 | Kristen Mulholland
Officer
|
Option | 5.6K | $573.0K |
| Feb 6, 2026 | Timothy Schmid
Officer
|
Option | 15.6K | $1.6M |
| Feb 6, 2026 | Kathryn E Wengel
Chief Technology Officer
|
Option | 38.9K | $4.0M |
| Feb 5, 2026 | Elizabeth Forminard
Officer
|
Option | 8.9K | $1.2M |
| Jan 26, 2026 | Joaquin Boix Duato
Chief Executive Officer
|
Sell | 100.0K | $22.1M |
| Nov 26, 2025 | John G Morikis
Director
|
Buy | 1.3K | $257.7K |
| Oct 17, 2025 | John C Reed
Officer
|
Sell | 21.7K | $4.2M |
| Oct 17, 2025 | John C Reed
Officer
|
Option | 21.7K | $3.4M |
| Sep 4, 2025 | Jennifer L Taubert
Officer
|
Sell | 56.5K | $10.0M |
| Sep 4, 2025 | Jennifer L Taubert
Officer
|
Option | 56.5K | $5.8M |
| Aug 29, 2025 | Elizabeth Forminard
General Counsel
|
Option | 11.5K | $1.3M |
| Aug 22, 2025 | Joaquin Boix Duato
Chief Executive Officer
|
Sell | 125.8K | $22.5M |
| Aug 22, 2025 | Joaquin Boix Duato
Chief Executive Officer
|
Option | 125.8K | $12.8M |
| Aug 15, 2025 | Joseph J Wolk
Chief Financial Officer
|
Sell | 16.8K | $3.0M |
| Aug 15, 2025 | Joseph J Wolk
Chief Financial Officer
|
Option | 16.8K | $1.7M |
| Jul 17, 2025 | John C Reed
Officer
|
Sell | 19.1K | $3.1M |
| May 1, 2025 | John C Reed
Officer
|
Grant | 25.3K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.